Designs, develops and manufactures components, assemblies and finished medical devices for medical device makers, including cardiovascular, heart-rhythm and neuromodulation products.
10-K for FY2025, filed Feb 23, 2026Integer Holdings Corporation, headquartered in Plano, Texas, is one of the world’s largest medical device contract development and…View ↗
The Cardio & Vascular product line leverages a global footprint to produce a full range of components, subassemblies, and finished devices…View ↗
The Cardiac Rhythm Management & Neuromodulation product line offers design, development and manufacturing capabilities for components…View ↗
Integer sells medical products, with most sales counted when goods ship; certain products with no other use are counted as work progresses when the contract allows payment for completed work. Standard payment terms range from 30 to 90 days.
10-K for FY2025, filed Feb 23, 2026The majority of the Company’s revenues consist of sales of various medical devices and products to large, multinational OEMs and their…View ↗
The Company recognizes revenue from contracts with customers as performance obligations are satisfied when the customer obtains control of…View ↗
The Company assesses whether promises are separate and distinct in the context of the contract. If promises are not separate and distinct…View ↗
10-K for FY2025, filed Feb 23, 2026
FY2025 revenue by product or service ↗$1.9B
10-K for FY2025, filed Feb 23, 2026
$1.9B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Cardio And Vascular
Sold outright
10-K for FY2025, filed Feb 23, 2026 |
60%
FY2022: 53%
|
Cardio And Vascular, FY2025
$1.1B Sources
|
Sold outright |
|
Cardiac Rhythm Management & Neuromodulation
Sold outright
10-K for FY2025, filed Feb 23, 2026 |
36%
FY2022: 40%
|
Cardiac Rhythm Management & Neuromodulation, FY2025
$668.8M Sources
|
Sold outright |
|
Other Markets
Sold outright
|
4.2%
FY2022: 7.3%
|
Other Markets, FY2025
$77.8M Sources
|
Sold outright |
Large multinational medical-device makers and their affiliated subsidiaries are the main buyers; Integer sells directly to them, with limited exceptions.
10-K for FY2025, filed Feb 23, 2026
10-K for FY2025, filed Feb 23, 2026
Sales Accounts Receivable 2025 2024 2023 December 31,2025 December 31,2024 Customer A 20% 18% 16% 19% 10% Customer B 15% 16% 17% 9% 9%…View ↗
Yes. It kept 6 cents of every revenue dollar as net income in FY2025 and turned 6 cents into free cash flow.
10-Q for Q3 FY2026, filed Oct 29, 2026
Open tableView ↗
8-K, filed Aug 4, 2026
Subject to the terms and conditions of the Merger Agreement, at the effective time of the Merger (the “Effective Time”), each share of…View ↗
8-K, filed Aug 3, 2026
In a separate press release issued today, Integer reported second quarter 2026 financial results. Given the pending transaction with KKR…View ↗
Growing. Revenue grew 52% in 4 years, from $1.2B in FY2021 to $1.9B in FY2025, about 11% a year.
Moved away from non-medical batteries
The older report described a separate non-medical battery business serving energy, military and environmental markets. The latest report describes a medical-technology focus and says Integer sold Electrochem, which served nonmedical applications.
10-K for FY2022, filed Feb 21, 2023 10-K for FY2025, filed Feb 23, 2026
Portable medical sales are being wound down
The older report presented rechargeable batteries and chargers for medical devices as part of a product line. The latest says sales are being transitioned to other suppliers ahead of a planned market exit.
10-K for FY2022, filed Feb 21, 2023 10-K for FY2025, filed Feb 23, 2026During 2021, we initiated plans to exit our portable medical market to enhance profitability and reallocate manufacturing capacity to…View ↗
Loading...